title: The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.
abstract: Idelalisib is a first in class, delta isoform specific, PI3-kinase inhibitor. Based on its high level of efficacy and acceptable safety profile, this oral drug has been approved by the US Food and Drug Administration as a single agent for the treatment of relapsed or refractory small lymphocytic lymphoma, and follicular non-Hodgkin lymphoma, and in combination with rituximab for patients with chronic lymphocytic leukemia. Adverse effects of particular concern include diarrhea, pneumonitis, and transient elevations of hepatic transaminase levels. Efforts to improve on the activity of this drug have included combinations with standard chemotherapy agents, such as bendamustine, and other targeted therapies, including checkpoint inhibitors. However, other combinations have been associated with life-threatening and fatal toxicities. Thus, the development of such regimens should be conducted carefully in the context of a clinical research study. Idelalisib has a vital role as second-line therapy for chronic lymphocytic leukemia, especially for patients with high-risk disease and multiple comorbidities, and studies are exploring the use of this agent as front-line therapy to improve the outcome of patients with indolent B-cell malignancies.
authors.affiliation: Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA.
authors.forename: Kruti Sheth
authors.initials: KS
authors.lastname: Nair
authors.affiliation: Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Cheson
keywords: PI3K; chronic lymphocytic leukemia; diarrhea; ibrutinib; idelalisib; pneumonitis; transaminitis; venetoclax